Clinical Trial

Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of MP0533 in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-01-04; most recent amendment 2026-06-05.
Status change: Recruiting → Active, Not Recruiting 2026-06-05
Trial Details
NCT Number NCT05673057
Lead Sponsor Molecular Partners AG
Conditions Leukemia, Myeloid, Acute, Newly Diagnosed
Enrollment 249 participants
Start Date 2022-12-29
Primary Completion 2026-05-29 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2026-06-09